IPI-493

DRUG2 trials

Sponsors

Infinity Pharmaceuticals, Inc.

Conditions

Advanced MalignanciesHematologic Malignancies

Phase 1

A Phase 1 Dose Escalation Study of IPI-493

TerminatedNCT00724425

Infinity Pharmaceuticals, Inc.Advanced Malignancies

Start: 2008-07-31End: 2011-07-31Updated: 2015-04-15

Dose Escalation of IPI-493 in Hematologic Malignancies

TerminatedNCT01193491

Infinity Pharmaceuticals, Inc.Hematologic Malignancies

Start: 2010-06-30End: 2011-07-31Updated: 2015-04-15